Mirodenafil dihydrochloride

Synonyms: SK-3530 dihydrochloride
Mirodenafil (SK3530) dihydrochloride 是一种口服有效、可逆、选择性的磷酸二酯酶 5 (PDE5) 抑制剂,也是一种糖皮质激素受体 (GR) 调节剂,可通过下调 Dkk1 的表达激活 Wnt/β-catenin 信号通路,可用于研究勃起功能障碍 (ED)、阿尔茨海默病 (AD) 和系统性硬化症 (SSc)。
产品编号: MS-E42050 纯度: 99.11% CAS No.: 862189-96-6 分子式: C26H39Cl2N5O5S 分子量: 604.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Mirodenafil (SK3530) dihydrochloride 是一种口服有效、可逆、选择性的磷酸二酯酶 5 (PDE5) 抑制剂,也是一种糖皮质激素受体 (GR) 调节剂,可通过下调 Dkk1 的表达激活 Wnt/β-catenin 信号通路,可用于研究勃起功能障碍 (ED)、阿尔茨海默病 (AD) 和系统性硬化症 (SSc)。

生物实验数据

生物活性 Mirodenafil (SK3530) dihydrochloride is an orally active, reversible and selective phosphodiesterase 5 (PDE5) inhibitor and a glucocorticoid receptor (GR) modulator that activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression, and can be used for research on erectile dysfunction (ED), Alzheimer's disease (AD) and systemic sclerosis (SSc).
IC50 & Target

PDE5

 

体外研究
(In Vitro)

Mirodenafil dihydrochloride (0-40 μM, 24 h) exerts neuroprotective functions via activating the cGMP/PKG/CREB signaling pathway.
Mirodenafil dihydrochloride (0-40 μM, 24 h) enhances neuronal survival by protecting the mitochondrial membrane potential and inhibiting apoptosis.
Mirodenafil dihydrochloride (0-40 μM) inhibits GSK-3β signaling, resulting in reduced tau phosphorylation, decreased Aβ production by inhibiting amyloidogenesis and activating the autophagosomal pathway.
Mirodenafil dihydrochloride inhibits the transcriptional activity of the glucocorticoid receptor (GR), and inhibits homodimerization of GR in HT-22 cells.
Mirodenafil dihydrochloride (0-100 μM, 24 h) inhibits TGF-β-induced phosphorylation of Smad2/3 and mRNA expression of the fibrosis marker in fibroblasts.

Western Blot Analysis

Cell Line: SH-SY5Y human neuroblastoma cells
Concentration: 0, 10, 20, 40 μM
Incubation Time: 24 h
Result: Significantly increased cGMP levels by about 200% in a dose-dependent manner. Reversed the Aβ-induced decrease in phosphorylated CREB in a dose-dependent manner. Aβ42 alone increased the levels of cleaved caspase-3 and cleaved PARP, whereas the combined treatment with mirodenafil markedly reduced the expression levels of both apoptotic markers.

RT-PCR

Cell Line: NIH3T3 mouse embryonic fibroblasts
Concentration: 0, 10, 100 μM
Incubation Time: 24 h
Result: The mRNA expression of COL1A1, α-SMA, and CTGF were induced by treatment with TGF-β1, and Mirodenafil significantly reduced the expression of these profibrotic genes.
体内研究
(In Vivo)

Mirodenafil dihydrochloride (4 mg/kg, IP, daily for 4 weeks) enhances the cognitive-behavioral performance in transgenic AD mice.
Mirodenafil dihydrochloride (0-10 mg/kg, Orally, daily for 3 weeks) ameliorates dermal fibrosis in a BLM-induced SSc mouse model by inhibiting the TGF-β signaling pathway, thereby suppressing the expression of collagen and profibrotic genes.

Animal Model: APP-C105 transgenic mice (13-month-old, male, n=6)
Dosage: 4 mg/kg
Administration: IP, daily for 4 weeks
Result: Improved cognitive function in the APP-C105 AD mice.
Animal Model: Male BALB/c mice (8 weeks old, four groups, n=10/group)
Dosage: 0, 5 or 10 mg/kg
Administration: Orally, daily for 3 weeks
Result: Ameliorated dermal fibrosis and downregulated the protein levels of fibrosis markers including COL1A1 and α-SMA in the BLM-induced SSc mouse model. Significantly decreased dermal thickness and collagen content.
性状 固体
颜色 White to off-white

化学信息

分子量 604.59
分子式 C26H39Cl2N5O5S
CAS No. 862189-96-6
别名 SK-3530 dihydrochloride

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.31 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (165.40 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 5 mg/mL (8.27 mM; 超声助溶 (<60°C))

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM1.6540 mL8.2701 mL16.5401 mL41.3503 mL
5 mM0.3308 mL1.6540 mL3.3080 mL8.2701 mL
DMSO10 mM0.1654 mL0.8270 mL1.6540 mL4.1350 mL
15 mM0.1103 mL0.5513 mL1.1027 mL2.7567 mL
20 mM0.0827 mL0.4135 mL0.8270 mL2.0675 mL
25 mM0.0662 mL0.3308 mL0.6616 mL1.6540 mL
30 mM0.0551 mL0.2757 mL0.5513 mL1.3783 mL
40 mM0.0414 mL0.2068 mL0.4135 mL1.0338 mL
50 mM0.0331 mL0.1654 mL0.3308 mL0.8270 mL
60 mM0.0276 mL0.1378 mL0.2757 mL0.6892 mL
80 mM0.0207 mL0.1034 mL0.2068 mL0.5169 mL
100 mM0.0165 mL0.0827 mL0.1654 mL0.4135 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础